Caribou Biosciences Inc Ordinary Shares CRBU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Caribou Biosciences to Evaluate Strategic Alternatives
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.41–0.42
- 52-Week Range
- $0.40–2.49
- Bid/Ask
- $0.42 / $0.42
- Shares Outstanding
- 107.21M
- Market Cap
- $44.75M
- Volume/Avg
- 51,772 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 97
- Website
- https://www.cariboubio.com
Valuation
Metric | CRBU |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.58 |
Price/Sales | 4.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CRBU |
|---|---|
Quick Ratio | 4.79 |
Current Ratio | 4.97 |
Interest Coverage | — |
Quick Ratio
CRBU
Profitability
Metric | CRBU |
|---|---|
Return on Assets (Normalized) | −59.14% |
Return on Equity (Normalized) | −85.87% |
Return on Invested Capital (Normalized) | −68.96% |
Return on Assets
CRBU
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|yLM$Z@ | LOCK|k!G&q | $138B | |||
| Moderna Inc MRNA | LOCK|%>?F%hH | LOCK|?c | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|yBf$mX | LOCK|<^!$L | $93B | |||
| argenx SE ADR ARGX | LOCK|f#gKy&R | LOCK|%^H | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&KDf$?> | LOCK|GFN | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Y^@J>yH | LOCK|%VT^? | $30B | |||
| Incyte Corp INCY | LOCK|##Bl^M# | LOCK|GGF | $24B | |||
| BioNTech SE ADR BNTX | LOCK|XgLjyZh | LOCK|%# | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$l#%d& | LOCK|L&$C | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|h@v>?$ | LOCK|FLJ | $15B |
United States